Form 4: Rapport Therapeutics Director Wendy B. Young Acquires Stock Options
SEC Form 4 Filing
Director Wendy B. Young acquired 29,756 stock options in Rapport Therapeutics on November 7, 2024.
Summary
- On November 7, 2024, Wendy B. Young, a director of Rapport Therapeutics, acquired 29,756 stock options.
- The exercise price of these options is $26.9.
- One-third of the shares underlying the option will vest on November 7, 2025, with the remaining shares vesting in 24 equal monthly installments, contingent upon continued service.
- The expiration date for these options is November 7, 2034.
Sentiment
Score: 5
Explanation: This is a neutral event, reflecting a standard insider transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership of securities by a company insider. It's a routine part of corporate governance and transparency.
Stakeholder Impact
- The acquisition of stock options by a director could align their interests more closely with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 11/07/2024 | Date of transaction: Wendy B. Young acquired stock options. |
| 11/07/2025 | Vesting start date: One-third of the shares underlying the option vest. |
| 11/07/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.